• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒病 2019(COVID-19)与心血管并发症。

Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications.

机构信息

Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, China.

Department of Anesthesiology, Peking Union Medical College Hospital, Beijing, China.

出版信息

J Cardiothorac Vasc Anesth. 2021 Jun;35(6):1860-1865. doi: 10.1053/j.jvca.2020.04.041. Epub 2020 Apr 30.

DOI:10.1053/j.jvca.2020.04.041
PMID:32451271
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7192093/
Abstract

The coronavirus disease-2019 (COVID-19) has become a global pandemic. It has spread to more than 100 countries, and more than 1 million cases have been confirmed. Although coronavirus causes severe respiratory infections in humans, accumulating data have demonstrated cardiac complications and poor outcome in patients with COVID-19. A large percent of patients have underlying cardiovascular disease, and they are at a high risk of developing cardiac complications. The basics of the virus, the clinical manifestations, and the possible mechanisms of cardiac complications in patients with COVID-19 are reviewed. Before an effective vaccine or medicine is available, supportive therapy and identifying patients who are at high risk of cardiac complications are important.

摘要

2019 年冠状病毒病(COVID-19)已成为全球性大流行。它已传播到 100 多个国家,确诊病例超过 100 万例。尽管冠状病毒会导致人类严重的呼吸道感染,但越来越多的数据表明,COVID-19 患者存在心脏并发症和不良预后。很大一部分患者患有基础心血管疾病,他们发生心脏并发症的风险很高。本文回顾了该病毒的基础知识、临床表现以及 COVID-19 患者心脏并发症的可能发生机制。在有效疫苗或药物问世之前,支持性治疗和识别心脏并发症高危患者非常重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ecf/7192093/281603760e5b/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ecf/7192093/281603760e5b/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0ecf/7192093/281603760e5b/gr1_lrg.jpg

相似文献

1
Coronavirus Disease-2019 (COVID-19) and Cardiovascular Complications.新型冠状病毒病 2019(COVID-19)与心血管并发症。
J Cardiothorac Vasc Anesth. 2021 Jun;35(6):1860-1865. doi: 10.1053/j.jvca.2020.04.041. Epub 2020 Apr 30.
2
Management of Cardiovascular Disease During Coronavirus Disease (COVID-19) Pandemic.心血管疾病在冠状病毒病(COVID-19)大流行期间的管理。
Trends Cardiovasc Med. 2020 Aug;30(6):315-325. doi: 10.1016/j.tcm.2020.05.004. Epub 2020 May 28.
3
Cardiovascular manifestations in severe and critical patients with COVID-19.COVID-19 重症及危重症患者的心血管表现。
Clin Cardiol. 2020 Jul;43(7):796-802. doi: 10.1002/clc.23384. Epub 2020 Jun 20.
4
Cardiovascular Implications of the COVID-19 Pandemic: A Global Perspective.《COVID-19 大流行对心血管的影响:全球视角》
Can J Cardiol. 2020 Jul;36(7):1068-1080. doi: 10.1016/j.cjca.2020.05.018. Epub 2020 May 16.
5
The "Three Italy" of the COVID-19 epidemic and the possible involvement of SARS-CoV-2 in triggering complications other than pneumonia.新冠疫情“三意大利”现象及 SARS-CoV-2 可能引发除肺炎外的并发症。
J Neurovirol. 2020 Jun;26(3):311-323. doi: 10.1007/s13365-020-00862-z. Epub 2020 Jun 16.
6
Cardiovascular Disease and SARS-CoV-2: the Role of Host Immune Response Versus Direct Viral Injury.心血管疾病与 SARS-CoV-2:宿主免疫反应与病毒直接损伤的作用。
Int J Mol Sci. 2020 Oct 30;21(21):8141. doi: 10.3390/ijms21218141.
7
Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review.新型冠状病毒病 2019(COVID-19)的病理生理学、传播、诊断和治疗:综述。
JAMA. 2020 Aug 25;324(8):782-793. doi: 10.1001/jama.2020.12839.
8
Potential Effects of Coronaviruses on the Cardiovascular System: A Review.冠状病毒对心血管系统的潜在影响:综述。
JAMA Cardiol. 2020 Jul 1;5(7):831-840. doi: 10.1001/jamacardio.2020.1286.
9
Myocardial involvement in coronavirus disease 19.新型冠状病毒肺炎的心肌受累情况
Herz. 2020 Dec;45(8):719-725. doi: 10.1007/s00059-020-05001-2. Epub 2020 Nov 20.
10
SCAI initiatives during the COVID-19 pandemic.新冠疫情期间的SCAI倡议。
Catheter Cardiovasc Interv. 2020 Nov;96(5):995-996. doi: 10.1002/ccd.29058. Epub 2020 Jun 20.

引用本文的文献

1
Acute type A aortic dissection patients undergoing surgical repair during the COVID-19 pandemic.在新冠疫情期间接受手术修复的急性A型主动脉夹层患者。
Medicine (Baltimore). 2025 Apr 25;104(17):e42249. doi: 10.1097/MD.0000000000042249.
2
Advances and Challenges in Antiviral Development for Respiratory Viruses.呼吸道病毒抗病毒药物研发的进展与挑战
Pathogens. 2024 Dec 31;14(1):20. doi: 10.3390/pathogens14010020.
3
Cardiac Hemodynamics, Tissue Oxygenation, and Functional Capacity in Post-COVID-19 Patients.新冠康复患者的心脏血流动力学、组织氧合及功能能力

本文引用的文献

1
Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19.新冠病毒病患者中的肾素-血管紧张素-醛固酮系统抑制剂
N Engl J Med. 2020 Apr 23;382(17):1653-1659. doi: 10.1056/NEJMsr2005760. Epub 2020 Mar 30.
2
Covid-19 in Critically Ill Patients in the Seattle Region - Case Series.西雅图地区危重症新冠患者-病例系列。
N Engl J Med. 2020 May 21;382(21):2012-2022. doi: 10.1056/NEJMoa2004500. Epub 2020 Mar 30.
3
Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19).新冠肺炎(COVID-19)患者的心脏受累。
Medicina (Kaunas). 2025 Jan 14;61(1):124. doi: 10.3390/medicina61010124.
4
Acute SARS-CoV-2 Infection and Incidence and Outcomes of Out-of-Hospital Cardiac Arrest.急性严重急性呼吸综合征冠状病毒 2 感染与院外心脏骤停的发生率和结局。
JAMA Netw Open. 2023 Oct 2;6(10):e2336992. doi: 10.1001/jamanetworkopen.2023.36992.
5
Adverse events following COVID-19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia.COVID-19 mRNA 疫苗接种后的不良反应:心血管并发症、血栓形成和血小板减少症的系统评价。
Immun Inflamm Dis. 2023 Mar;11(3):e807. doi: 10.1002/iid3.807.
6
Potential Regulation of NF-κB by Curcumin in Coronavirus-Induced Cytokine Storm and Lung Injury.姜黄素对冠状病毒诱导的细胞因子风暴和肺损伤中NF-κB的潜在调节作用
Int J Prev Med. 2022 Dec 26;13:156. doi: 10.4103/ijpvm.IJPVM_565_20. eCollection 2022.
7
Emodin in cardiovascular disease: The role and therapeutic potential.大黄素在心血管疾病中的作用及治疗潜力
Front Pharmacol. 2022 Dec 23;13:1070567. doi: 10.3389/fphar.2022.1070567. eCollection 2022.
8
Real-World Management of Pharmacological Thromboprophylactic Strategies for COVID-19 Patients in Japan: From the CLOT-COVID Study.日本COVID-19患者药理学血栓预防策略的真实世界管理:来自CLOT-COVID研究
JACC Asia. 2022 Dec;2(7):897-907. doi: 10.1016/j.jacasi.2022.09.005. Epub 2022 Dec 15.
9
[Influence of arterial hypertension on the clinical profile and prognosis of patients hospitalized for COVID-19 in the city of Bukavu, in the Democratic Republic of Congo : Prospective cohort study].[动脉高血压对刚果民主共和国布卡武市因 COVID-19 住院患者的临床特征和预后的影响:前瞻性队列研究]
Ann Cardiol Angeiol (Paris). 2023 Feb;72(1):25-30. doi: 10.1016/j.ancard.2022.10.006. Epub 2022 Oct 26.
10
The impact of HMG-CoA reductase inhibitors use on the clinical outcomes in critically ill patients with COVID-19: A multicenter, cohort study.HMG-CoA还原酶抑制剂的使用对COVID-19危重症患者临床结局的影响:一项多中心队列研究。
Front Public Health. 2022 Aug 11;10:877944. doi: 10.3389/fpubh.2022.877944. eCollection 2022.
JAMA Cardiol. 2020 Jul 1;5(7):819-824. doi: 10.1001/jamacardio.2020.1096.
4
Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19).COVID-19 患者的致命结局对心血管的影响。
JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017.
5
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.113 例新冠肺炎死亡患者的临床特征:回顾性研究。
BMJ. 2020 Mar 26;368:m1091. doi: 10.1136/bmj.m1091.
6
Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China.新冠肺炎住院患者中心脏损伤与死亡的相关性研究:中国武汉。
JAMA Cardiol. 2020 Jul 1;5(7):802-810. doi: 10.1001/jamacardio.2020.0950.
7
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.羟氯喹和阿奇霉素治疗 COVID-19:一项开放标签非随机临床试验的结果。
Int J Antimicrob Agents. 2020 Jul;56(1):105949. doi: 10.1016/j.ijantimicag.2020.105949. Epub 2020 Mar 20.
8
Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study.武汉儿童 2019 冠状病毒病重症患者的临床特征:单中心观察性研究。
World J Pediatr. 2020 Jun;16(3):251-259. doi: 10.1007/s12519-020-00354-4. Epub 2020 Mar 19.
9
Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan.宿主对重症新型冠状病毒肺炎的易感性及宿主风险评分的建立:武汉以外地区487例病例的研究结果
Crit Care. 2020 Mar 18;24(1):108. doi: 10.1186/s13054-020-2833-7.
10
Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin.糖皮质激素联合人免疫球蛋白治疗冠状病毒暴发性心肌炎
Eur Heart J. 2021 Jan 7;42(2):206. doi: 10.1093/eurheartj/ehaa190.